Home | Publications | Country | USA / Canada | Canada place holder
place holder place holder

Canada


The Pharmaceutical Market: Canada


Publication Date   August 2007
Publisher   Espicom
Product Type   Report
Pages   106
ISBN Number   not applicable
Product Code   ESP559
Ask a question about this product?

Price £595.00

approximately: $1,051 | €754

Summary


This In-Depth Pharmaceutical Market Reports Are Ideal For Executives Wanting To Understand The Key Drivers In Pharmaceutical Markets And Have Access To A Wealth Of Statistical Data. Each Report Opens With An Outlook Section That Provides Analysis Of The Market, 5-Year Market Forecasts, National Data Projections, Market Outlook And Key Developments Such As Regulation, Pricing/Reimbursement, Intellectual Property, Health Facilities And Government Policy. The Report Also Provides Extensive Background Information, Population Trends, Health Status, Health Expenditure, Organisation & Administration, Hospital Services, Medical Personnel, Healthcare Development, Market Access Information, Trade Data For Raw Materials And Finished Products And Essential Industry Contacts. Included With The Report Are 3 Free Quarterly Updated Outlook Reports, Enabling You To Keep Up To Date With Market Developments For A Year.

Canadians Have Traditionally Enjoyed A High Standard Of Healthcare, With Health Outcomes Among The Best In The World. Canada's National Health Service Is Managed And Delivered By The Provincial And Territorial Governments, Which Operate Health Insurance Plans Collectively Known As Medicare. These Are Obliged To Conform To The Principles Of The Canada Health Act: Universality, Accessibility, Comprehensiveness, Portability And Public Administration. The Increasing Cost Of Medicare Has Been The Subject Of Much Debate In Recent Years.

The Pharmaceutical Market Is Differentiated From The Usa By Its Government Control Of Drug Prices, Through The Patented Medicines Price Review Board. This Generally Keeps Prices For Branded Medicines Below Those In The Usa, And Has Led To Much Arguing In The Usa Over The Legality And Desirability Of Exporting Drugs From Canada. In 2005, However, It Looks As If Canada Will Legislate To Significantly Reduce This Trade.

The Canadian Market Is Fragmented, With Reimbursement Decisions Resting With The Various Provincial Governments. This Can Lead To Wide Variations In Coverage For Particular Products. Concerns About The Efficiency And Modernity Of Canada's System Have Led To Several Major Initiatives In Recent Years, Not Least The Ten Year Plan Finalised In October 2004. This Is A C$41 Billion Agreement Between The National Government And The Provinces To Fund Improvements In A Number Of Key Areas, Such As Reducing Waiting Lists, Boosting Home Care And Improving Access To Primary Care. A National Pharmaceutical Plan Is Also Part Of The Deal, Which Aims To Improve Access To Drug Treatment Across The Country.

Most Large Multinational Firms Conduct Manufacturing And/Or R&D In Canada. Locally-Owned Firms Tend To Be Manufacturers Of Generics Or Development-Stage Biotech Products. The Leading Canadian Manufacturer Is Apotex, A Privately-Held Generic Company. The Generic Industry Is Currently Fighting Against Government Proposals To Amend Canada's Patent Laws; The Amendments Would Seek To End The Process Of 'evergreening', But Would Also Create A Longer Period Of Data Exclusivity.

Content


  • Executive Summary
  • Pharmaceutical Market
    • Current Size
    • Hospital Drug Expenditure
    • Manufacturers. Sales
    • Generics
    • OTCs
    • Projections
    • Outlook
    • Market Structure
    • Domestic production
    • Abbott Laboratories Ltd
    • Apotex
    • Aventis Pharma (sanofi-aventis)
    • Cangene Corporation
    • Draxis Health
    • Genpharm Inc
    • GlaxoSmithKline (GSK)
    • Merck Frosst & Co
    • Novartis Pharmaceuticals Canada Inc
    • Novopharm Ltd. (Teva)
    • Pfizer Canada Inc.
    • Ranbaxy Canada
    • ratiopharm
    • Schering Canada Inc
    • Exports
    • Imports
    • Research & Development
    • Market developments
    • Amendments to Canada.s food and drug and patent regulations provoke controversy
    • Evergreening
    • First report into Generic Drug Prices finds Canada expensive
    • Canadian pharmaceutical industry mulls over Ontario.s Bill 102
    • CGPAs reactions
    • The Rx&D response
    • Economic impact of generics worth C$1 billion in Quebec
    • National Pharmaceutical Strategy
  • Canada Pharma Outlook
    • Pharma Outlook espicom BUSINESS INTELLIGENCE
    • ii Quarter II
    • Jean Chretien Pledge to Africa Act
    • KEY NATIONAL DATA PROJECTIONS
    • Methodology and Sources
    • List of Tables
    • Summary of the Canadian Pharmaceutical Market, 2007
    • Public/Private Drug Expenditure, 1975-2005 (C$ millions)
    • Prescribed Drug Expenditure by Source of Finance, 2005 (C$ Millions)
    • Personal expenditure on medical care and health services, 1996-2005 (C$ millions)
    • Drug Expenditure by Province/Territory, 2001 & 2005 (C$ Millions)
    • Drug Expenditure in Hospitals by Province, 2003 (C$ millions)
    • Manufacturers' Sales of Patented Drug and Generics, 1990-2005 (C$ Billion)
    • Sales of Patented Drugs by Therapeutic Area, 2002-2005 (C$ Million)
    • Market Projections, 2006-12
    • SWOT Analysis of the Canadian Pharmaceutical Market, 2007
    • Canadian Pharmaceutical Manufacturers Shipments, 2003-06 (C$/US$)
    • Exports of Pharmaceuticals, 2000-2006 (US$000s)
    • Pharmaceutical Export Trends
    • Canadian Exports to the USA, 2000-2006 (US$000s)
    • Exports of Retail Medicaments to the USA by Province, 2001-06 (US$ millions)
    • Imports of Pharmaceuticals, 2000-2006 (US$000s)
    • Pharmaceutical Import Trends
    • Leading Suppliers of Raw Materials, 2004-06 (US$000s)
    • Leading Suppliers of Medicaments, 2004-06 (US$000s)
    • Total R&D Spending and R&D to Sales Ratios, 1991-2005 (C$ Million)
    • Key Data, 2007-12
  • Pharma Outlook Canada
    • Pharma Outlook espicom BUSINESS INTELLIGENCE
    • Quarter II 2007 iii
    • List of Figures
    • % Growth in Pharmaceutical Expenditure, 1980-2005
    • Exports by Category, 2006 (%)
    • Leading Destinations, 2006 (%)
    • Imports by Category, 2006 (%)
    • Leading Suppliers, 2006 (%)